title: Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice.
authors: aDepartment of Internal Medicine - Infectious Diseases bDepartment of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands cKomfo Anokye Teaching Hospital dKwame Nkrumah University of Science and Technology, Kumasi, Ghana eSt George's University of London, London, UK.
authors: Sandor
authors: S
authors: Klis
authors: Tjip S
authors: TS
authors: van der Werf
authors: Richard O
authors: RO
authors: Phillips
authors: Fred S
authors: FS
authors: Sarfo
authors: Mark
authors: M
authors: Wansbrough-Jones
authors: Ymkje
authors: Y
authors: Stienstra
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D054312:Buruli Ulcer / Q000150:complications* / Q000188:drug therapy*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D011804:Quinolines / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D044966:Anti-Retroviral Agents; D001372:Aza Compounds; D011804:Quinolines